Looking forward to this event starting this Friday

ICYMI: Dana-Farber's Kornelia Polyak, MD, PhD, who received the 2023 AACR Distinguished Lectureship in Breast Cancer Research, explored age-related mammary gland changes in her #AACR24 plenary session.

➡️ https:/dfci.widen.net/s/pgc8mq7m8v/aacr-annual-meeting-presentations-2024

So thankful to Karen and Rob Hale providing their support to allow us to support our amazing division of breast surgery investigators. Brigham and Women’s Department of Surgery Dr. E Mittendorf christinaminami Eliza Hersh Lorentzen, MD

Big news to start the day: DESTINY-Breast06 Phase III trial show a PFS advantage from trastuzumab deruxtecan (T-DXd) compared to chemotherapy in patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following 1+ lines of endocrine therapy.…

HER2 is about to change again. In DESTINY-Breast06, T-DXd significantly improved PFS in chemo-naive patients with HER2-low and HER2- #ultralow MBC. OS immature. Presented at ASCO?

Press Release: astrazeneca.com/media-centre/p…

Navigating HER2-low: aacrjournals.org/cancerdiscover…

Here we are with Dr Sarah Sammons from Dana-Farber’s Breast Oncology Center

simposiocancerdemama.cl

Here's the #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (April 22nd-28th, 2024). #ClinicalResearch #CancerTreatment #BCSM #BreastCancer Research

'It takes a mind-shift, venturing out into the community, building relationships, and approaching the partnership with humility,' said Ludmila Svoboda, MSN, RN, OCN, highlighting Dana-Farber's Cancer Care Equity Program at #ONSCongress .

More Than 25% of Cancer Survivors Report Significant Levels of Disability After Cancer Diagnosis, According to New Study Chao Cao @danafarber #oncology
onclive.com/view/more-than…

The #FDA approval of Enhertu for patients with HER2-positive solid tumors is an “unprecedented approval,” Dr. Sarah Sammons (Dr Sarah Sammons) of Dana-Farber @dfci_breastonc told CURE®.

Read more about this treatment option: curetoday.com/view/enhertu-m…

What a tour de force! Fantastic review of LCIS and invasive lobular carcinoma by Tari King MD #GBCC2024 . Dana-Farber’s Breast Oncology Center Brigham and Women’s Department of Surgery

Dana-Farber’s Breast Oncology Center is leading a trial on the use of #ColdCaps in preventing hair loss with novel #BreastCcancer therapies including sacituzumab, eribulin, or trastuzumab deruxtecan. Contact us for info about the study or visit: dana-farber.org/breast-oncolog…… #ScalpCooling ; PI Elahe Salehi DNP

Happy Administrative Professionals Day! Today is a reminder to acknowledge and celebrate the invaluable contributions of individuals who often work tirelessly behind the scenes. Their professionalism, adaptability, and positive attitude make a significant difference! Thank you 🩵

Join us 5/10 for the Annual Cancer Disparities Research Symposium!

Hosted by Christopher Lathan, MD, MS, MPH, & Karen Burns White, it will focus on Equity in Clinical Trials Participation in recognition of National Minority Cancer Awareness.

ms.spr.ly/6016cxYAY

Full house today at our #USCAP2024 symposium! Thank you Korentzelos Dimitris, Stuart Schnitt & Adam L. Booth, MD for making a strong case for using #AI in routine #pathology practice to help improve #cancer care. Dana-Farber WUSM Pathology & Immunology UPMC USCAP #digitalpathology #cancer diagnostics

Goodbye #USCAP2024 ! Thank you to the hundreds of visitors who came for a demo, chat & ☕ at the booth or clinical sessions & to the trailblazing researchers who made the case for deploying #AI in #patholgoy TODAY! Korentzelos Dimitris Stuart Schnitt Adam L. Booth, MD Zaibo Li USCAP

Young survivors of #BreastCancer face difficult decisions about their future #fertility beginning at the time of diagnosis. A study from Kimia Sorouri, MD, MPH et al explores post-cancer conception and pregnancy experiences for these survivors.

acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

#IWD2024

What happens when #hereditarycancer testing identifies two pathogenic variants? We compared cancer risk in >600 individuals with double PVs to those with a single PV in this publication with Dana-Farber. hubs.ly/Q02qphlm0 #genechat #genechat pubs @nbagaglu Brittany Bychkovsky, MD

Our study at the Dana-Farber has been recently published in Genetics in Medicine Open! It is such a pleasure to be a member of the Dana-Farber Cancer Genetics&Prevention family and to work with the Ambry Genetics team! #hereditarycancer Carrie Horton Brittany Bychkovsky, MD Huma Rana, MD, MPH judy garber

World experts in breast cancer brain metastases:
'We suggest default inclusion of pts with BrMs into clinical trials of ADCs.'